| 抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展 |
| |
| 引用本文： | 刘辰,方思尹,顾操,吴晋晖.抗视网膜脉络膜新生血管性疾病治疗药物靶点的研究进展[J].基础医学与临床,2022(2):325-329. |
| |
| 作者姓名： | 刘辰 方思尹 顾操 吴晋晖 |
| |
| 作者单位： | 海军军医大学第一附属医院眼科;海军军医大学第三附属医院眼科 |
| |
| 基金项目： | 上海市浦江人才项目(17PJD041);海军军医大学,未来战争医学防护技术研发专项(19WLMS-03);上海市中医药管理局(ZHYY-ZXYJHZX-202024)。 |
| |
| 摘 要： | 新生血管性年龄相关性黄斑变性(nAMD)、糖尿病视网膜病变(DR)等眼底病继发形成新生血管,是致盲的重要原因之一。抗血管内皮生长因子(VEGF)治疗是当前主流疗法。但仍存在部分患者对其疗效欠佳等局限,临床仍需要开发新的药物靶点。
|
| 关 键 词： | 视网膜 脉络膜 新生血管 药物靶点 |
Research progress on drug targets for anti-retinal and choroidal neovascular diseases |
| |
| LIU Chen,FANG Si-yin,GU Cao,WU Jin-hui.Research progress on drug targets for anti-retinal and choroidal neovascular diseases[J].Basic Medical Sciences and Clinics,2022(2):325-329. |
| |
| Authors: | LIU Chen FANG Si-yin GU Cao WU Jin-hui |
| |
| Institution: | (Department of Ophthalmology, the First Affiliated Hospital, Navy Military Medical University, Shanghai 200433;Department of Ophthalmology, the Third Affiliated Hospital, Navy Military Medical University,Shanghai 200438, China) |
| |
| Abstract: | The appearance of new blood vessels in the neovascular age-related macular degeneration(nAMD),diabetic retinopathy(DR),and other ocular diseases is one of the important reasons for blindness.Anti-vascular endothelial growth factor(VEGF)drugs are the current mainstream.However,some patients have poor efficacy and other adverse reactions.There is still a need to develop new drugs. |
| |
| Keywords: | retina choroid revascularization drug targets |
| 本文献已被 维普 等数据库收录！ |
